345 PARK AVENUE SOUTH, NEW YORK, NY
Announces First Quarter 2026 Financial Results and Provides a Business Update
Annual Report to Security Holders
Protara Therapeutics Reports 68% Six-Month CR Rate in BCG-Unresponsive Patients
Financial Results, Press Release
Interim Safety and Tolerability of TARA - 002 in Patients with BCG - Naive and Unresponsive High - grade Non - muscle Invasive Bladder Cancer in ADVANCED - 2
Protara Therapeutics Completes $5.75 Public Offering of 13,043,479 Shares
Protara Therapeutics Enters Underwriting Agreement for $75 Million Offering
ADVANCED - 2: Preliminary Efficacy and Safety Data in BCG - naïve Participants with High - grade Non - muscle Invasive Bladder Cancer
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)